Psyence Biomedical Ltd. (PBM)
| Market Cap | 2.91M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.94M |
| Shares Out | 1.15M |
| EPS (ttm) | -34.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 39,633 |
| Open | 2.620 |
| Previous Close | 2.620 |
| Day's Range | 2.460 - 2.680 |
| 52-Week Range | 1.920 - 74.938 |
| Beta | 0.32 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 19, 2026 |
About PBM
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder... [Read more]
Financial Performance
Financial StatementsNews
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine ther...
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine ther...
Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway
The Put Option Agreement positions Psyence BioMed for potential significant future equity participation in one of the world's most advanced psychedelic pharmaceutical grade manufacturers, thereby secu...
Psyence BioMed Announces Settlement of Shareholder Litigation
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company") today announced that it has entered into a settlement agreement to resolve a direc...
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation (reverse...
Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that it adjourned its annual and special meeting of shareholders (...
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced that it has decided to postpone the previously announced effectiv...
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine ther...
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine ther...
Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial
With approximately $9.5 million in cash reserves and no debt, the Company is ready to leverage strengthened vertical integration as clinical-grade psilocybin moves into Phase IIb trials With approxima...
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine ther...
Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program
First publicly listed company to actively investigate psilocybin's potential impact on longevity NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or ...
Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine ther...
Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Psyence BioMed (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for...
Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine ther...
Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and Ibogaine ther...
Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine ther...
Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased to announce that its strategic partner, PsyLabs – a leader in the produ...
PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares
TORONTO, June 25, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psilocybin in mental health a...
PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares
TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental h...
Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025
Investors, Entrepreneurs, and Industry Experts to Convene at the Premier Psychedelic Science Business Forum hosted by Multidisciplinary Association for Psychedelic Studies (MAPS) Denver, Colorado--(Ne...
Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements
New York, New York--(Newsfile Corp. - June 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced that it has received formal notification from the Nasda...
Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial
New York, New York--(Newsfile Corp. - May 27, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company developing nature-derived psilocybin therapies for u...
Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split
New York, New York--(Newsfile Corp. - May 1, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced the effective date of its 1-for-7.97 share consolidation ...
Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
New York, New York--(Newsfile Corp. - April 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") announced today that it received a notification letter dated April 16,...